JIUDIAN PHARMACEUTICAL: Expected revenue growth of 10% to 20% year-on-year for the fiscal year 2025
Zhitong
JIUDIAN PHARMACEUTICAL stated during an institutional research that the company's operating revenue for the fiscal year 2025 is expected to grow by 10% to 20% year-on-year, and the non-recurring net profit is also expected to grow by 10% to 20% year-on-year
